The implementation of glucagon-like peptide-1 (GLP-1)-based drugs for the treatment of obesity has been an incredible advance in the field, enabling up to 25% decreases in body weight in many...
The first glucagon-like peptide-1 (GLP-1)-based therapeutic was approved by Health Canada in 2011 for the treatment of hyperglycemia in patients with Type 2 diabetes. Little was it suspected at...